Cargando…

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products. Bypassing agents to control bleeding episodes are recommended for these patients, but their efficacy is diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Dargaud, Yesim, Escuriola‐Ettingshausen, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606027/
https://www.ncbi.nlm.nih.gov/pubmed/34849451
http://dx.doi.org/10.1002/rth2.12631